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The leadership of the International 
Federation of Psoriasis Associations 
(IFPA) envisioned a global meeting 
for people with the ability to improve 
the quality of life of individuals with 
psoriasis and psoriatic arthritis. They 
imagined physicians, scientists, patient 
association leaders, and industry rep-
resentatives—from all over the world 
and for the first time—working together 
to share current information about the 
diseases. They hoped to hold an inter-
national meeting that would improve 
communication among these parties, 
increase research collaboration, and 
gain global recognition of the serious-
ness of psoriasis and psoriatic arthritis. 
The first World Psoriasis and Psoriatic 
Arthritis Conference, held in Stockholm, 
Sweden, 31 May to 4 June 2006,* was 
the fulfillment of that vision.
This unique meeting attracted nearly 
700 dermatologists, rheumatologists, 
scientists, patient leaders, and industry 
representatives from 47 countries and 
six continents who came together for 
the first time to focus on psoriasis and 
psoriatic arthritis from clinical, basic 
research, and health services perspec-
tives. Mark Lebwohl, MD (US), served 
as the honorary chairman, and Kenneth 
Gordon, MD (US), and Philip Mease, 
MD (US), served as co-chairs. The scien-
tific steering committee included Dafna 
Gladman, MD (Canada), Christopher 
Ritchlin, MD (US), and Mona Stahle, 
MD, PhD (Sweden).
The vision of the meeting was to 
present all information from the per-
spective of both the skin and the joints. 
The conference offered an extensive sci-
entific program to study the most recent 
advances in four basic areas of psoriatic 
disease: genetics, immunology, quality 
of life and the burden of disease, and 
clinical research. Each session was co-
chaired by a dermatologist and a rheu-
matologist: genetics (Jonathan Barker, 
MD (UK), and Dafna Gladman, MD), 
immunology (Mona Stahle, MD, PhD, 
and Christopher Ritchlin, MD), quality 
of life and the burden of disease (Peter 
van de Kerkhof, MD (The Netherlands), 
and Douglas Veale, MD (Ireland)), and 
clinical research (Kenneth Gordon, 
MD, and Philip Mease, MD). Each 
session began with review lectures 
examining the topic of interest from 
the dermatologic and rheumatologic 
perspectives. The key lectures were fol-
lowed by presentations selected from 
submitted abstracts. Concurrent ses-
sions were held for the patient organi-
zations to highlight key findings in each 
of these areas.
The conference opened with a lec-
ture from Professor Hans Wigzell, the 
chief scientific adviser to the Swedish 
Government and former chairman of 
the Nobel Committee for Medicine. 
He spoke eloquently on the scientific 
challenges of psoriasis. Sessions on the 
first day focused on psoriasis genetics 
and immunology. Psoriasis and psori-
atic arthritis have different genetic ori-
gins and genetic susceptibility markers. 
Invited lectures by Jonathan Barker, 
MD, and Proton Rahman, MD, PhD 
(Canada), explained the genetic etiol-
ogy of psoriasis and psoriatic arthri-
tis, respectively. Oral presentations of 
selected abstracts followed, including 
presentations on how HLA-Cw*0602 
and HLA-ER genotypes interact in 
psoriasis, the role of chromosome 6P 
haplotypes in psoriatic arthritis, and a 
genetic study of California twin pairs.
The immunology and biology ses-
sion began with a lecture on psoriasis 
pathogenesis by Frank Nestle, MD (UK). 
Two overview lectures were presented 
on the immunobiology of psoriasis and 
psoriatic arthritis by Joerg Prinz, MD 
(Germany), and Christopher Ritchlin, 
MD (US), respectively. Abstract oral 
presentations included the roles of sub-
stance P and receptor neurokinin-1 in 
psoriasis, the role of pathogenic T cells 
in the tonsils and its relationship to skin, 
and novel innate response cytokines in 
psoriatic arthritis. The session closed 
with an invited lecture on animal mod-
els of psoriasis by Brian Nickoloff, MD, 
PhD (US).
The second day’s sessions concerned 
quality of life and the burden of disease. 
Overviews of quality of life in derma-
tology and rheumatology were pre-
sented by Andrew Finlay, MD (UK), and 
Arthur Kavanaugh, MD (US), respec-
tively. Abstract presentations described 
patient surveys in psoriasis and psoriat-
ic arthritis, new measurements includ-
ing the World Health Organization 
International Classification of 
Functioning, Disability, and Health and 
the Koo-Menter Psoriasis Instrument 
and PQOL-12, and interviews reveal-
ing how psoriasis affects family mem-
bers and the role played by stress. 
Invited lectures included quantitative 
assessment of adherence to medica-
tion by Steven Feldman, MD, PhD (US), 
and relevance of quality-of-life assess-
ment in the treatment of psoriasis by 
John de Korte, MD (The Netherlands). 
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Andrew Findlay, MD (UK), and Arthur 
Kavanaugh, MD (US), closed the ses-
sion by describing the quality of life in 
dermatology and quality-of-life issues 
in psoriatic arthritis.
A special session on the global 
impact of psoriasis was chaired by Mark 
Lebwohl, MD, Lars Ettarp (Sweden), 
and Gail Zimmerman (US). The ses-
sion opened with a presentation by 
Jean Paul Ortonne, MD (France), on the 
EUROPSO Survey and one by Steven 
Feldman, MD, PhD, on the US 2001 
Benchmark Survey. Presenters spoke 
of the challenges of treating psoriasis 
in Africa, Asia, South America, Europe, 
and North America. The speakers 
included Gail Todd, MD (South Africa), 
Ibrahim Hassan Galadari, MD (United 
Arab Emirates), Silvia Fernandez Barrio 
(Argentina), Tae-Yoon Kim, MD (South 
Korea), Hoseah Waweru, MD (Kenya), 
and Michael David, MD (Israel). 
Although the disease manifests simi-
larly, lack of access to care and unavail-
ability of a full range of treatments are 
serious disadvantages in some areas of 
the world. Poverty, geographic isolation, 
lack of information, and even cultural 
customs increase the difficulty patients 
can experience. These presentations 
spurred discussion of the importance of 
developing nonprofit psoriasis associa-
tions, building relationships with medi-
cal professionals, and advocating with 
governments as strategies to decrease 
the burden of the disease worldwide.
The third day was dedicated to clini-
cal research. The full-day program con-
sisted of a morning session on natural 
history, disease characteristics, and 
epidemiology of psoriasis and psori-
atic arthritis and an afternoon session 
on clinical research. A lecture on the 
historical perspective of psoriasis was 
given by Kenneth Gordon, MD. The 
topics of invited lectures included new 
elements of epidemiology and comor-
bidities of psoriasis by Gerald Krueger, 
MD (US), outcome measure science 
of psoriasis by Robert Chalmers, MD 
(UK), and new elements of epidemi-
ology and clinical aspects of psori-
atic arthritis by Dafna Gladman, MD. 
Abstract oral presentations were given 
on the hormonal effects of pregnancy 
on psoriasis, the development and 
evaluation of PASE (a self-administered 
psoriatic arthritis screening and evalu-
ation tool), CASPAR classification crite-
ria for psoriatic arthritis, and the impact 
on the liver of long-term methotrexate 
treatment in psoriasis.
In the clinical research afternoon 
session, overview lectures were given 
on systemic agents and biologic agents 
in psoriasis by Kristian Reich, MD 
(Germany), traditional systemic agents 
in psoriatic arthritis by Neil McHugh, 
MD (UK), and biologic agents in pso-
riatic arthritis by Philip Mease, MD. 
Oral abstract presentations were given 
on the results of a phase II study of 
CNTO 1275 in psoriasis, the efficacy 
of anakinra in psoriatic arthritis, and 
clinical efficacy, safety, and patient-
reported outcome of EDUCATE, a 
multicenter, community-based, open-
label study of the effect of etanercept 
on skin and joint disease in patients 
with psoriatic arthritis. The concluding 
lectures were given by Eric Ruderman, 
MD (US), on drug safety in psoriasis 
and psoriatic arthritis, and by Alice 
Gottlieb, MD, PhD (US), on new treat-
ments in development.
Following the meeting, an all-day ses-
sion was devoted to patient advocacy. 
The session stimulated dialogue among 
patient associations, the medical com-
munity, and industry on how they can 
best work together. Patient associations 
are central to the management of pso-
riasis and can be very effective in setting 
global research agendas and encour-
aging collaborations among scientific 
communities throughout the world.
It is safe to say that the conference 
surpassed expectations in the quality of 
scientific presentations, the number of 
attendees from around the world, and 
the extent of interchange and network-
ing that occurred in scientific sessions, 
at posters, during meals and breaks, 
and at social events planned by the 
Swedish hosts. In particular, the fruit-
ful dialogue and collaborative spirit 
engendered between dermatologists 
and rheumatologists, many of whom 
had not known each other, and with 
members of the pharmaceutical indus-
try and IFPA members was exciting to 
witness. We look forward to a similar 
quality of interchange at the second 
World Psoriasis and Psoriatic Arthritis 
Conference in 2009.
The list of members of the Scientific 
Steering Committee and the Scientific 
Council, as well as the abstracts pre-
sented in poster or oral presentations at 
the meeting, are published in this issue.
*The fi rst World Psoriasis and Psoriatic 
Arthritis Conference was held at the 
Stockholm City Conference Centre in 
Stockholm, Sweden, 31 May–4 June 2006.
